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Background: Abnormal activation of STAT3 and miR-21 plays a vital role in progression and invasion of solid
tumors. The cyclin-dependent kinase 5 (CDK5) is reported to contribute to cancer metastasis by regulating
epithelial-mesenchymal transition (EMT). However, the role of STAT3/miR-21 axis and CDK5 in head and neck
squamous cell carcinoma remains unclear.
Methods: We measured the expression of miR-21, CDK5 and EMT markers in 60 HNSCC tumor samples. We used
Immunohistochemistry and in situ hybridization assay to examine the role of STAT3/miR-21 axis and CDK5 activation in
the invasiveness of HNSCC. The clinical survival relevance was analyzed by Kaplan-Meier analysis and univariate/
multivariate COX regression model. Multiple approaches including scratch, transwell chamber assay and other
molecular biology techniques were used to validate the anti-invasion effect of targeting miR-21 in Tca8113
and Hep-2 cell lines in vitro. Furthermore, whether miR-21 depletion inhibits HNSCC invasion in vivo was
confirmed in Tca8113 xenograft tumor model.
Results: The expression of miR-21 and CDK5 were significantly correlated with lymph node metastasis in HNSCC. Hep-
2 and Tca8113 cell lines showed co-overexpression of miR-21 and CDK5. WP1066 or asON-miR-21 treatment depleted
miR-21 and CDK5 expression and significantly inhibited migration or invasion in Hep-2 and Tca8113 cells. The
expression levels of CDK5/p35, N-cadherin, vimentin, β-catenin were inhibited while E-cadherin level was increased by
miR-21 depletion in vitro and in vivo. Conversely, ectopic CDK5 overexpression significantly induced tumor cell motility
and EMT. Moreover, ectopic CDK5 overexpression in Hep-2 and Tca8113 cells rescued the observed phenotype after
miR-21 silencing or WP1066 treatment.
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Conclusions: miR-21 cooperates with CDK5 to promote EMT and invasion in HNSCC. This finding suggests that CDK5
may be an important cofactor for targeting when designing metastasis-blocking therapy by targeting STAT3/miR-21
axis with STAT3 inhibitor or miR-21 antisense oligonucleotide. This is the first demonstration of the novel role of STAT3/
miR-21 axis and CDK5/CDK5R1 (p35) in metastasis of HNSCC.
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Presently there are 600,000 new HNSCC patients world-
wide annually [1]. Approximately up to 50 % HNSCC
patients achieved 5-year overall survival, suggesting a
poor mean survival for this cancer type [2]. Lymph node
metastasis or other distant metastasis is one of the most
significant factors responsible for the observed poor clin-
ical outcome. Epithelial mesenchymal transition (EMT)
is considered as a vital process of metastasis, and thus it
may significantly contribute to the progression of
HNSCC [3–5].
The oncogenic miR-21 gene is located in chromo-
some17q23.2 and is evolutionally conserved in verte-
brates including humans. MiR-21 is known to play an
essential role in regulating biological behaviors in many
malignancies [6–8]. MiR-21 is also associated with sev-
eral biomarkers and therapeutic targets in multiple epi-
thelium cancers such as oral squamous cell carcinoma
(OSCC) [9], renal cancer [10], colorectal cancer [11],
and etc. MiR-21 has been demonstrated as a key regula-
tor of biological behaviors of cancer cells, including
apoptosis [10], proliferation [12], EMT [13], migration
and invasion [14]. Accumulating evidence demonstrates
that miR-21 participated in EMT via several signal path-
ways. Luo et al. found that STAT3/miR-21 activation by
IL-6 was associated with arsenite-induced EMT of hu-
man bronchial epithelial (HBE) cells [15]. Our previous
research also suggested that inhibition of STAT3/miR21
axis with WP1066, a small-molecule STAT3 inhibitor,
suppressed HNSCC cell growth and sensitized cells to
cisplatin [16, 17].
The neuronal kinase CDK5, which functions in migra-
tion, was recently reported to be activated in human
cancers and implicated in promoting metastasis [18].
CDK5 activation regulates prostate cancer cell motility
and metastatic potential [19]. Inhibition of CDK5 activity
reduces the tumorigenic and metastatic properties of
pancreatic cancer cells [18]. In an orthotropic xenograft
model of human pancreatic cancer, inhibition of CDK5
reduces tumor growth and metastasis [18]. CDK5 func-
tions through its regulatory subunit, p35, in multiple
caner types. In medullary thyroid carcinoma (MTC),
CDK5, p35 and p25 are highly expressed, and CDK5
promotes tumorigenesis and tumor progression via
down-regulating its downstream target, Retinoblastomagene (Rb) [20]. An elevated expression of CDK5 and p35
in lung cancer cells is associated with enhanced lung
cancer cell migration and invasion [21].
Although miR-21 and CDK5 respectively regulates
HNSCC metastasis, whether miR-21 promotes HNSCC
metastasis via regulating CDK5 has not been documented
in literature. In the present study, we for the first time
demonstrated that miR-21 promotes HNSCC lymph node
metastasis and EMT via upregulating CDK5.
Methods
Human tissue samples, IHC staining and ISH
A total of 60 HNSCC tumor samples were included in
this study. All the patients received radical resection of
tumor and neck lymph node dissection at Tianjin Med-
ical University Cancer Institute & Hospital between
January 2008 and December 2012. Ten tissues samples ad-
jacent to tumors were also collected and used as controls.
Institutional Human Subject Research Review Committee
of Tianjin Medical University approved all procedures. All
cases were grouped into positive or negative lymph node
metastasis according to the American Joint of Cancer
Committee’s Lip and Oral Cancer TNM staging system
(2010 version) [22]. All tumor samples and tissues adjacent
to tumor were paraffin-embedded and sectioned for
routine immunohistochemistry (IHC) staining and in
situ hybridization. Hybridization was performed with
locked nucleic acid (LNA)-modified antisense miR-21
probe (Boster, China) and IHC for CDK5 (Cell Sig-
naling Technology, USA), N-cadherin (Cell Signaling
Technology, USA), Vimentin (BD Bio, CA, USA), β-
catenin (Cell Signaling Technology, USA), STAT3/-p
(Cell Signal Technology, USA), Ki-67 (Zhongshan,
China), cleaved caspase 3 (Cell Signaling Technology,
USA) and E-cadherin (Cell Signaling Technology,
USA). The In situ hybridization (ISH) and IHC assays
were performed as previously described [12].
Cell culture and transfection
The human Hep-2 and Tca8113 cell lines were pur-
chased from the China Center for Type Culture Collec-
tion (Wuhan, China) and maintained in modified Eagle’s
medium (MEM) and RPMI-1640 (Invitrogen, USA) sup-
plemented with 10 % fetal bovine serum (Gibco, USA).
WP1066 (Calbiochem, Germany) was dissolved in DMSO
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cells were treated with WP1066 for 48 h at a concentration
of 4.5 μM. The asON was transfected by using Lipofecta-
mine 2000 (Invitrogen, USA) at a final concentration of
300 nmol/L and 233 nmol/L, respectively, according to the
manufacturer’s instructions. 48 h after transfection, cells
were harvested for total RNA or miRNAs isolation, and
protein extraction. The CDK5 plasmid (CDK5(BC005115)-
GV141) was synthesized by Gene Chem Company, China.
RNA extraction and real-time PCR
Total RNAs were extracted by using the Trizol Reagent
(Life technology, USA) in accordance with the manufac-
turer’s instructions. Both RT and PCR primers were pur-
chased from Gene Pharma (Shanghai, China). Expression
of mature miR-21 was measured using miR-21 QPCR kit
(Beyotime Biotechnology, China). Relative quantification
was conducted using amplification efficiencies derived from
cDNA standard curves. Relative gene expressions were ob-
tained. Quantitative analysis of change in expression levels
was performed using a real-time PCR machine (7500 ABI;
USA). The PCR procedure was performed on the Real-
time PCR (Bio-Rad, USA) as described previously [12]. U6
was used as an internal control.
Western blot analysis
WP1066 and asON treated Hep-2 and Tca8113 cells were
collected for total protein extraction. Extracted proteins
were transferred to PVDF membranes (Millipore, USA)
and probed with the primary antibodies against N-cadherin
(Cell Signaling Technology, USA), vimentin (BD Bio, CA,
USA), β-catenin (Cell Signaling Technology, USA), p-β-
catenin (Cell Signaling Technology, USA), E-cadherin (Cell
Signaling Technology, USA), CDK5 (Cell Signaling Tech-
nology, USA), STAT3/-p (Cell Signal Technology, USA). β-
actin (Zhongshan, China) and Histone H2A (Cell Signaling
Technology, USA) was used as a loading control in total
cell extracts and nuclear extracts.
Immunofluorescence staining
For immunofluorescence staining, Hep-2 and Tca8113
cells were seeded on coverslips and fixed with 4 % para-
formaldehyde (PFA, Sigma), treated with 1 % Bovine
serum albumin (Equitech-Bio, USA) for 30mins and in-
cubated with the antibodies described above overnight at
4 °C. Alexa Fluor 546Goat Anti-Rabbit IgG (1:400 dilu-
tions, Zhongshan, China) was added for 1 h at 37 °C.
DAPI reagent was used to stain the cell nuclei. The cells
were visualized using FV-1000 laser scanning confocal
microscopes.
Wound healing and transwell assays
Hep-2, Tca8113 and Tca8113P160 cells layers were
scratched using a 20 μl sterile pipette tip to form woundgaps. The wound location in the six-well plates was
marked. Cells were photographed to record the wound
width (0 h). Cells were cultured in serum-free medium.
Photographs were taken after 24, 48 and 72-h at the
marked wound location to measure the cell migration
ability. Cell invasion assays were performed using trans-
well membranes coated with Matrigel (BD Bio, CA,
USA). The lower chamber was filled with 10 % FBS.
After 48 h, cells remaining in the upper chamber were
removed with cotton swabs, while invading cells were
fixed with 3 % paraformaldehyde (Santa Cruz, USA),
stained with crystal violet (Solarbo, China). Cells pene-
trated through the polyethylene terephthalate membrane
were counted in ten representative microscopic fields
(200 ×magnification).Tca8113 xenograft tumor assay
Tianjin Medical University Animal Care and Use Com-
mittee approved all animal experimental protocols. Four
nude mice were injected with 107 of Tca8113 cells sub-
cutaneously. Mice were monitored daily and three out of
four mice formed tumors. Ten days after xenografting,
when the tumor size reached approximately 7 mm in
diameter, the tumors were surgically removed, cut into
pieces of 1–2 mm3 and re-implanted into the left inguinal
region of 20 recipient mice. The mice were randomly di-
vided into four groups (DMSO group, nsON-treated group,
WP1066-treated group and asON-treated group) for per-
spective treatment and observation. At the end of the 23rd
day of observation, the mice were sacrificed and the xeno-
graft tumors were removed for formalin fixation and prep-
aration of paraffin-embedded sections.Statistical analysis
Data were analyzed using software SPSS 17.0. The inter-
relationship of miR-21, CDK5 and EMT related protein
expression with lymph node metastasis status was ana-
lyzed using χ2 or Fisher exact test. Spearman’s correlation
test was used to analyze the correlation of miR-21, CDK5
and the EMT related proteins with lymph node metastasis
status. The results were expressed as mean +/- standard
error (SE), which represented the average of at least three
experiments and each of them was performed in triplicate.
Statistics was determined using the analysis of variance
test. A p value less than 0.05 was considered statistically
significant.Statement of human tissue and animals experiments
We confirmed that all the protocols on human tissue
examination and animal experiments were approved by the
Committee of Medical Ethics at Tianjin Medical University.
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Overexpression of miR-21/CDK5 is associated with EMT
and lymph node metastasis in HNSCC
In the present study, we determined the expression level
of miR-21, CDK5 and EMT-related proteins in 60
HNSCC samples. The clinical staging was determined
according to American Joint of Cancer Committee
(AJCC) Lip and Oral Cancer TNM staging system (2010
version). As shown in the representative IHC staining
and in situ hybridization staining in Fig. 1a and b, expres-
sion of miR-21 (red) and CDK5 was elevated in lymph
node positive group compared with the negative group
(χ2 = 8.906, p =0.003; χ2 = 14.102, p =0.000). MiR-21 and
CDK5 were significantly associated with lymph node
metastatic status (R = 0.385, p =0.002; R = 0.527,p =0.000).
As shown in Fig. 1c and Additional file 1: Figure S2B, theFig. 1 Differential expression of miR-21, CDK5 and EMT-related proteins in
expression level in lymph node with different status of metastasis is shown forexpressions of STAT3 and EMT markers were enhanced
in lymph node positive group with significant correlation
to lymph node metastatic status in HNSCC samples, for
N-cadherin (X2 = 21.365,p =0.000;R = 0.647, p =0.000),
vimentin (X2 = 7.358, p =0.007;R = 0.350, p =0.006), E-
cadherin (X2 = 21.609, p =0.000;R = -0.645, p =0.000), β-
catenin (X2 = 5.742, p =0.017;R = 0.354, p =0.002). All
HNSCC samples were analyzed using Kaplan-Meier ana-
lysis and a multivariate COX regression model. Analysis
showed that the expression of miR-21, CDK5, EMT
markers, and lymph node metastasis are closely correlated
(Additional file 2: Table S1). Univariate analysis showed
significant relationships between the Overall survival (OS)
and higher T stage, high expression of CDK5, MiR-21, N-
cadherin, Vimentin, low expression of E-cadherin, and
lymph node metastasis (p < 0.05). Furthermore, T stagelymph node (LN) metastasis and LN-negative HNSCC samples. Protein
a, MiR-21; b, CDK5; and c, N-cadherin, vimentin, E-cadherin and β-catenin
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13.607; p < 0.05), and N-cadherin expression (HR: 1.795-
38.098; p < 0.05) were identified as the independent factors
of the OS, which were analyzed by Multivariate Analysis.
Protein level of CDK5 and EMT markers were verified by
Western blot in the aforementioned corresponding sam-
ples of HNSCC (Additional file 3: Figure S1B).
WP1066 inhibited MiR-21/CDK5 in HNSCC cell lines Hep-2
and Tca8113 in vitro
To investigate the involvement of miR-21 and CDK5 in
HNSCC, we examined the expression of miR-21 inFig. 2 WP1066 inhibits MiR-21/CDK5 in HNSCC cell lines Hep-2 and Tca811
in Hep-2 and Tca8113 cells. c MiR-21 expression level alteration after WP10
treated with WP1066. e STAT3 and pSTAT3 expression after WP1066 treatmdifferent HNSCCs cell lines (Cal-27, Hep-2, Tscca,
Tca8113, and Tca8113p160). By qRT-PCR and Western
blot analysis, we showed that the expression levels of
miR-21 and CDK5 were remarkably higher in Hep-2 and
Tca8113 cells than other HNSCCs cell lines, as showed
in Fig. 2a and b. We also validated the protein level of
STAT3 and pSTAT3 in all the tested cell lines, showing
significantly increased pSTAT3 in Hep-2 and Tca8113
cells (Additional file 3: Figure S1A), suggesting a positive
correlation of expression of miR-21, CDK5, STAT3 and
activated pSTAT3. Therefore, Hep-2 and Tca8113 cells
were chosen for further investigation.3. a MiR-21 expression in Hep-2 and Tca8113 cells. b CDK5 expression
66 or asON treatment. d CDK5 expression in Hep-2 and Tca8113 cells
ent in Hep-2 and Tca8113 cells
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we used WP1066, a specific STAT3 small-molecule in-
hibitor, and antisense oligonucleotide (asON) to sup-
press miR-21 activity. MiR-21 relative expression was
examined after asON exposure for optimal time and
dose, the nsON was used as a control group. The opti-
mal time and dose of WP1066 treatment in Hep-2 and
Tca8113 cells were demonstrated in our previous report
[16, 17]. As shown in Fig. 2c, miR-21 expression was sig-
nificantly decreased after WP1066 or asON treatment.
Meanwhile, CDK5 expression was suppressed by
WP1066 in both Hep-2 and Tca8113 cells (Fig. 2d). Con-
sistent with our previous report, STAT3 and pSTAT3 ex-
pression were effectively inhibited by WP1066 when
compared with parental and DMSO-treated Hep-2 and
Tca8113 cells (Fig. 2e).
Reduction of miR-21 impaired HNSCC migration, invasion
and EMT by regulating CDK5/p35 in vitro
We used asON and WP1066 to antagonize miR-21 in
Hep-2 and Tca8113 cells. nsON and DMSO were used
as controls. After 48 h of treatment, scratch and trans-
well chamber assay were employed to measure antagon-
istic effect in in vitro cell migration and invasion. The
number of migrating and invading cells in asON and
WP1066-treated cultures were reduced relative to the
control cells (p < 0.05, Fig. 3a, b), demonstrating that
both asON and WP1066 could impair the ability of
Hep-2 and Tca8113 cells migration and invasion. More-
over, we examined the MMP-2/MMP-9 expression levels
in Hep-2 and Tca8113 cells after WP1066 and asON ex-
posure by Western blot. As shown in Fig. 3c, both
MMP-2 and MMP-9 expression was decreased in
WP1066 and asON groups. All these results demon-
strated that knockdown of miR-21 had a suppressive ef-
fect on the migration and invasion ability of HNSCC
cells in vitro. We then focused on the effect of
knocking-down miR-21 on the EMT-phenotypes of
Hep-2 and Tca8113 cells. Western blot showed that in
both Hep-2 and Tca8113 cells treated with asON and
WP1066, E-cadherin expression level was elevated while
the N-cadherin expression was attenuated. In addition, a
decreased expression of vimentin was also observed. Im-
portantly, the β-catenin expression in nucleus and cyto-
plasm were both decreased (Fig. 4a, c), suggesting that
antagonism of miR-21 by asON and WP1066 led to
EMT reversal in Hep-2 and Tca8113 cells. Immunofluor-
escence (IF) staining showed a notable reduction of nu-
clear and cytoplasmic β-catenin in asON and WP1066
groups compared with the control group. We also ob-
served inhibition of N-cadherin and vimentin in asON
and WP1066-treated cells, compared with untreated
cells. Meanwhile, E-cadherin exhibited opposite expres-
sion after treatment (Fig. 4d, Additional file 1: FigureS2A). The alteration of these EMT-related proteins after
asON or WP1066 exposure suggests that the EMT in
Hep-2 and Tscca8113 cells was suppressed.
To further elucidate that inhibition of miR-21 re-
versed EMT through CDK5/p35, CDK5 and p35 ex-
pression were detected by Western blot analysis. In
Fig. 4b, it showed that CDK5 and p35 were signifi-
cantly down regulated by asON and WP1066 in
Hep-2 and Tca8113 cells, suggesting miR-21 regu-
lates EMT process in a CDK5/p35 dependent
manner.
Reduction of miR-21 results in reversal of EMT by regulat-
ing CDK5 in HNSCC in vitro and in vivo
In vitro experiments demonstrated that miR-21 reversed
EMT process via CDK5/p35. We thus employed a Tca8113
xenograft tumor model to confirm this effect in vivo. The
growth rates in WP1066 and asON group were suppressed
compared to the control and DMSO groups (Fig. 5a). The
impaired tumor growth is a consequence of both decreased
proliferation and increased apoptosis as demonstrated by
IHC staining of the tumors for Ki-67 and cleaved caspase
3, respectively (Additional file 1: Figure S2C). ISH analysis
showed that miR-21 was inhibited by WP1066 and asON
(Fig. 5d). IHC staining and western blot demonstrated de-
creased expression levels of STAT3, pSTAT3, CDK5, N-
cadherin, vimentin and β-catenin and increased expression
of E-cadherin, as observed in both WP1066- and asON-
treated groups in xenograft tumors (Fig. 5b, c, Additional
file 1: Figure S2C, Additional file 3: Figure S1D). We fur-
ther validated that CDK5 is a required component for
miR-21 to regulate EMT and invasion. CDK5 was overex-
pressed in Tca8113p160 cells, and we observed increased
expression of EMT markers (Additional file 3: Figure S1E),
enhanced migration and invasion in Tca8113p160 cells
(Additional file 3: Figure S1 F, G). Moreover, CDK5 overex-
pression reverted the inhibition of EMT markers ex-
pression by asON and WP1066 in Hep-2 and
Tca8113 cells (Additional file 3: Figure S1C), suggest-
ing that CDK5 overexpression in HNSCC cells is suf-
ficient to induce tumor cell motility via modulating
EMT. These results not only support co-regulation of
miR-21 and CDK5, but also establish a causal link
connecting miR-21, CDK5 and cancer cell migration,
invasion and metastasis.
Discussion
In the present study, miR-21 inhibition was shown to re-
verse the EMT process in HNSCC cells by regulating
CDK5/CDK5R1 (p35) with antisense oligonucleotide
(asON) or a STAT3 inhibitor WP1066.
The tumor cells undergoing EMT is a characteristic of
acquiring migratory and invasive mesenchymal phenotypes.
Diverse upstream signaling is implicated in this process. Of
Fig. 3 miR-21 blockade reduces migration and invasion of Hep-2 and Tca8113 cells in vitro. a Wound-healing assay of Hep-2 and Tca8113 cells.
b Transwell invasion of Hep-2 and Tca8113 cells. Cells were placed in the upper well of the transwell plate and FBS was added into the lower well
of the serum-free media. After 48 h of incubation, the percentage of invaded cells was calculated. (original magnification, x200). c Western blotting of
MMP-2/-9 expression in Hep-2 and Tca8113 cells after WP1066 and asON treatment
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role by triggering the translocation of β-catenin to the nu-
cleus, leading to the activation of EMT-related target genes
and ultimately promoting EMT [23]. Zhang et al. also re-
ported that activation of Wnt/β-catenin pathway is poten-
tially responsible for the EMT phenotype in SGC7901/
ADR cells [24]. In our study, the EMT reversal is supported
by notable alteration of nucleus-cytoplasm expression of β-
catenin by IF and IHC.MicroRNAs are defined as a subset of small non-coding
RNA, which are less than 22 nucleotides long. In general,
they function as negative regulators of target genes at
transcriptional and post-transcriptional level. Some of
them act as tumor-suppressors while other may act as
tumor-promoters. Recently, several miRNAs such as miR-
21, have been shown to be involved in EMT [25, 26]. Our
previous study has demonstrated that reduction of miR-21
induces glioma cell apoptosis via activating caspases 9 and
Fig. 4 miR-21 blockade reverses EMT by regulating CDK5/p35 in HNSCC cells in vitro. a Expression of EMT-related proteins after asON or WP1066
treatment, analyzed by western blot with normalization to β-actin. b Expressions of CDK5 and p35 after asON and WP1066 treatment, determined
by western blot with normalization to β-actin. c β-catenin level in nucleus and cytoplasm, analyzed by western blot with normalization to Histone
H2A. d Subcellular location of EMT related markers after asON or WP1066 treatment, observed by immunofluorescence staining (original
magnification, x100)
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man glioblastoma cells through EGFR pathway [12]. How-
ever, the mechanisms by which miR-21 regulates EMT is
not clear. Han et al. showed that AKT and ERK1/2 path-
ways are required for miR-21 in mediating EMT and CSC
phenotype by targeting PTEN [27]. Similarly, miR-21 in-
hibits its targets-PTEN and sulfatase-1 (hSulf-1) expres-
sion in hepatocellular carcinoma (HCC) cells and finally
enhances HCC cell proliferation and movement [28].
Meanwhile, miR-21 directs EMT and enhances the inva-
sive potential of transformed human bronchial epithelial
cells by targeting PDCD4 [29]. However, Wang et al.found that ectopic expression of miR-21 could overcome
TGF-β growth-inhibitory effect but had no effect on EMT
of TGF-β in HaCaT cells [13]. Our results suggest that
knockdown of miR-21 could reverse the process of EMT
in HNSCC cells via CDK5/p35.
CDK5 is a small serine/threonine cyclin-dependent
kinase that belongs to the family of CDKs. In contrast to
the cell cycle-related CDKs (e.g. CDKs 1, 2, 4, or 6),
CDK5 is not implicated in cell cycle control [30]. In-
stead, CDK5 is involved in neuronal migration and de-
velopment during embryogenesis [31]. In neurons,
CDK5 has been reported to interact with β-catenin
Fig. 5 miR-21 blockade leads to reversal of EMT via regulating CDK5 in vivo. a The growth curves of Tca8113 xenograft tumors treated with DMSO,
nsON, WP1066, and asON. b HE and IHC staining of CDK5. c IHC staining for alteration of EMT markers (original magnification, x400). d ISH for miR-21
inhibition by WP1066 and asON. e A hypothesis schema demonstrating the relationship among miR-21, STAT3 and CDK5/p35 in EMT of HNSCC
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cadherin by altering the phosphorylation levels of β-
catenin [32, 33]. Demelash et al. reported that induction
of CDK5 regulated lung cancer cell migration through
Achaete-scute complex homologue-1 (ASH1). ASH1 dir-
ectly modulates the expression ofp35 gene in small cell
lung cancer cells [21]. Furthermore, CDK5 can also
regulate endothelial cell migration and angiogenesis,
suggesting CDK5 may serve as a novel target for anti-
angiogenic therapy [34].
It was reported that miR-21 targets a number of im-
portant molecules such as PTEN, PDCD4, TIMP3 and
TMP1 [35, 36]. CDK5 is also involved in neuregulin-
dependent activation of phosphatidylinositol 3-kinase
(PI3K) and Akt activity [37], and promotes pancreatic β-
cell survival via Fak-Akt signaling pathways [38]. In the
present study, we attempted to demonstrate that CDK5
was the functional target of miR-21. Our results suggest
that the miR-21/CDK5 axis could partially mediate
tumor cell mobility and EMT by targeting STAT3 inHNSCC. Moreover, our previous study revealed that ab-
normal activation of miR-21/CDK5 axis was associated
with breast cancer lymph node metastasis [39].
Although several studies have established that miR-21
could promote EMT in tumor cells by a number of mech-
anisms, it is for the first time that we demonstrate CDK5
regulation by miR-21 to promote metastasis in HNSCC.
Our findings demonstrated the importance of miR-21/
CDK5signaling in tumor cell migration and invasion
in vitro and in vivo. Our studies suggest the intrinsic con-
nection between CDK5 and miR-21 in modulating EMT
in HNSCC. Based on these observations, we believe that
targeting miR-21/CDK5 might be a novel and feasible ap-
proach for managing metastasis from HNSCC. Innovative
strategies targeting miR-21 and CDK5 are currently being
pursued in our labs.
Conclusions
MiRNA-21 promotes metastasis of HNSCC via regulat-
ing CDK5/CDK5R1 (p35) to enhance EMT. Blocking
Sun et al. Molecular Cancer  (2015) 14:213 Page 10 of 11miR-21 with STAT3 inhibitor WP1066 effectively re-
versed EMT.
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location of E-cadherin, N cadherin and beta-catenin after asON or WP1066
treatment. B, IHC staining of STAT3 and vimentin in tumor tissue sections in
positively correlation to lymph node metastasis of HNSCC patients. C, IHC
showing the altered expression of STAT3/pSTAT3, Ki67 and cleaved caspase
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of CDK5 and EMT markers in relation to the status of lymph node metastasis
of HNSCC tissues. C, Ectopic overexpression of CDK5 in Hep-2 and Tca8113
cells and resulting revert of EMT after miR-21 silencing or WP1066 treatment.
D, Expression of CDK5 and EMT markers in mouse xenografts tissues after
WP1066 or asON treatment. E, Expressions of EMT markers after CDK5 plasmid
transfection in Tca8113P160 cells. F, Induction of tumor cell motility and EMT
after ectopic CDK5 overexpression in transwell assay in Tca8113p160 cells. G,
Induction of tumor cell motility and EMT after ectopic CDK5 overexpression
in scratch assay in Tca8113p160 cells. (JPG 16931 kb)
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